# BLIND POINT-IN-TIME FORECASTING TASK
You are a professional regulatory forecaster. This file contains 20 independent forecasting snapshots about
DIFFERENT regulatory matters. Treat each snapshot on its own; do not carry information between snapshots.

Rules:
1. For each snapshot, "today" is its CUTOFF DATE. Use only the evidence shown plus general knowledge of how the
   regulatory process usually behaves (base rates, typical durations). Do not use any world-state fact learned after
   the cutoff: later election results, leadership changes, court rulings, agency decisions, dates or outcomes are
   unknown, even if you remember them. A future event stated in cutoff-valid evidence may be considered only as an
   uncertain plan or possibility, never as a later-known result. Every factual driver in "notes" or "scenarios" must
   be supported by the shown evidence or be a general process base rate.
2. Do NOT use any specific memory of what happened to this particular matter after the cutoff. If you recognise the
   matter and believe you know its later outcome, set "recognised_outcome": true and forecast from cutoff-valid
   evidence only. Never state or hint at the remembered result.
3. The evidence shown may be only a subset of what was public; do not infer anything from the absence of a
   document type. Some snapshots show no documents at all — then forecast from title, regulator, process and date.
4. "Decisive action" is defined per snapshot. Probabilities in "p" are CUMULATIVE: probability the decisive action
   is published within 7/30/60/90/180 days AFTER the cutoff (non-decreasing; "180d" is the headline action
   probability). Delays, stalls, withdrawals and no-action outcomes are common in regulation: be calibrated, use
   the full 0–1 range when evidence warrants, and do not default to 0.5.
5. "next": the NEXT official step within 180 days (mutually exclusive, sums to 1): final_action,
   revised_or_further_consultation (revised draft, supplemental proposal, extended/reopened comment period,
   further consultation or hearing), formal_withdrawal, no_further_official_step.
6. "content": CONDITIONAL on the decisive action happening, its form relative to the most recent proposal visible
   (sums to 1): as_proposed (substantially as proposed), softened (narrower scope, lower stringency, higher
   thresholds, longer transition, carve-outs), tightened, mixed (some softened, some tightened),
   different_mechanism.
7. "scenarios": up to 3 concrete policy-content scenarios CONDITIONAL on action (probabilities sum ≤ 1), each with
   a short mechanism and, where the evidence has numbers (thresholds, rates, dates, amounts), predicted
   parameter ranges. Cite evidence labels (E1, E2 …) that support/contradict it.
8. If the evidence is too thin to forecast meaningfully, set "insufficient_evidence": true but still give your best
   base-rate probabilities.

OUTPUT: read the output file named in your instructions (it contains a placeholder) and replace its ENTIRE content
with ONE JSON object of exactly this shape (no comments, no trailing text):
{"forecasts": [
  {"id": "<snapshot id>",
   "p": {"7d": 0.00, "30d": 0.00, "60d": 0.00, "90d": 0.00, "180d": 0.00},
   "next": {"final_action": 0.00, "revised_or_further_consultation": 0.00, "formal_withdrawal": 0.00, "no_further_official_step": 0.00},
   "content": {"as_proposed": 0.00, "softened": 0.00, "tightened": 0.00, "mixed": 0.00, "different_mechanism": 0.00},
   "scenarios": [{"s": "short label", "p": 0.00, "mech": "mechanism, <=25 words", "params": {"parameter": "predicted range"}, "ev": ["E1"], "contra": []}],
   "notes": "<=40 words: main drivers of your forecast",
   "missing": ["<=3 items of missing information that would most change the forecast"],
   "recognised_outcome": false,
   "insufficient_evidence": false}
]}
One entry per snapshot, in any order, using the exact snapshot ids below.

---
## SNAPSHOT S63a588af0a
CUTOFF DATE (today): 2020-07-04
Regulator: FDA (US)
Matter: FDA draft guidance: Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated With Internal or External Hemorrhoids
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-12-06 | official-forward (B) | draft_guidance_availability_notice | "Development of Locally Applied Corticosteroid Products for the Short-Term Treatment of Symptoms Associated With Internal or External Hemorrhoids; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Development of Locally Applied Corticosteroid Products for the Short- Term Treatment of Symptoms Associated with Internal or External Hemorrhoids." This draft guidance will serv
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Development of Locally Applied Corticosteroid Products for the Short- Term Treatment of Symptoms Associated with Internal or External Hemorrhoids." This draft guidance will serve as a focus for continued discussions among the Division of Gastroenterology and Inborn Error Products, pharmaceutical sponsors, the academic community, and the public.
---
## SNAPSHOT S5d13dfa561
CUTOFF DATE (today): 2022-07-21
Regulator: FDA (US)
Matter: FDA draft guidance: Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-09-23 | official-forward (B) | draft_guidance_availability_notice | "Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency or we) is announcing the availability of a draft guidance for industry #254 entitled "Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products." FDA's Center for Veterinary Medicine (CVM) is issuing this guidance for sponsors, f
   Excerpt: The Food and Drug Administration (FDA or Agency or we) is announcing the availability of a draft guidance for industry #254 entitled "Donor Eligibility for Animal Cells, Tissues, and Cell- and Tissue-Based Products." FDA's Center for Veterinary Medicine (CVM) is issuing this guidance for sponsors, firms, individuals, and establishments that participate in the manufacture of, or perform any aspect of, the donor eligibility determination for animal cells, tissues, and cell- and tissue-based products (ACTPs), which meet the definition of new animal drugs under the Federal Food, Drug, and Cosmetic Act (FD&C Act). Donor eligibility is a critical component of current good manufacturing practices (CGMPs) when manufacturing ACTPs. A donor should be considered eligible to donate ACTPs only if screening of the donor shows that the donor is free from risk factors for, and clinical evidence of, infection with relevant disease agents and diseases, and the donor (and product/source material) test results for relevant disease agents are negative or nonreactive.
---
## SNAPSHOT Sbc75a10375
CUTOFF DATE (today): 2024-11-26
Regulator: FDA (US)
Matter: FDA draft guidance: Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning-Enabled Device Software Functions
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2023-03-30 | official-forward (B) | draft_guidance_availability_notice | "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning-Enabled Device Software Functions; Draft Guidance for Industry and Food and Drug Administration St" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions." This draft guidance de
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Marketing Submission Recommendations for a Predetermined Change Control Plan for Artificial Intelligence/Machine Learning (AI/ML)-Enabled Device Software Functions." This draft guidance demonstrates FDA's commitment to developing innovative approaches to the regulation of machine learning- enabled medical devices and describes an approach that would often be the least burdensome and would support iterative improvement through modifications to machine learning-enabled device software functions (herein referred to as ML-DSF) while continuing to ensure device safety and effectiveness. This draft guidance provides recommendations on the information to be included in a Predetermined Change Control Plan (PCCP) in a marketing submission for an ML-DSF. Such a plan describes the anticipated ML-DSF modifications and the associated methodology to implement those modifications, which would be reviewed in the marketing submission to ensure the continued safety and effectiveness of the device without necessitating additional marketing submissions for each modification described in the
---
## SNAPSHOT Sc2232ca070
CUTOFF DATE (today): 2024-07-29
Regulator: FDA (US)
Matter: FDA draft guidance: Voluntary Malfunction Summary Reporting Program for Manufacturers
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2022-12-09 | official-forward (B) | draft_guidance_availability_notice | "Voluntary Malfunction Summary Reporting Program for Manufacturers; Draft Guidance for Industry and Food and Drug Administration Staff; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers." We are publishing this notice of availability for this draft guidance document to help manufacturers better under
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of the draft guidance entitled "Voluntary Malfunction Summary Reporting (VMSR) Program for Manufacturers." We are publishing this notice of availability for this draft guidance document to help manufacturers better understand and use the VMSR Program. It is intended to further explain, but not change, the conditions of the VMSR Program. This draft guidance is not final nor is it for implementation at this time.
---
## SNAPSHOT Sb069491414
CUTOFF DATE (today): 2026-08-17
Regulator: SEBI (IN)
Matter: SEBI consultation: framework for an IT Resilience Index for market infrastructure institutions
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-03-25 | official-forward (B) | consultation_paper | "Consultation Paper on Framework of IT Resilience Index for Market Infrastructure Institutions (MIIs)" | www.sebi.gov.in
   Claims: Proposes creation of an 'IT Resilience Index' (ITRI) for market infrastructure institutions, computed periodically on a pre-decided set of parameters. / States the objective is to let MIIs compare the health/efficacy of their IT systems over time and to create a uniform set of metrics and weights to compare ITRI across MIIs. / Notes MIIs had already built a working model of the index, discussed in meetings of SEBI's Technical Advisory Committee (TAC).
   Excerpt: The objective of the consultation paper is to seek views on creation of IT Resilience Index (ITRI) for MIIs that would be computed periodically on a pre-decided set of parameters and which would provide insights to the MII on health of its IT systems across various dimensions. Based on the discussions with MIIs, an initial framework of ITRI for MIIs was formulated. The MIIs have implemented a working model of such index and the results were subsequently discussed in various meetings of SEBI's Technical Advisory Committee (TAC).
---
## SNAPSHOT Sb62394e6db
CUTOFF DATE (today): 2026-05-20
Regulator: SEBI (IN)
Matter: SEBI consultation: extending the early pay-in margin benefit to options contracts in the commodity derivatives segment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sd61ab30b7a
CUTOFF DATE (today): 2021-09-05
Regulator: FDA (US)
Matter: FDA draft guidance: Biomarkers and Surrogate Endpoints in Clinical Studies To Support Effectiveness of New Animal Drugs
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sd6e4570abc
CUTOFF DATE (today): 2025-12-25
Regulator: FDA (US)
Matter: FDA draft guidance: International Cooperation on Harmonisation of Technical Requirements for Registration of Veterinary Medicinal Products; Effectiveness of Anthelmintics: Specific Recommendations ...
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Saf577dd1e1
CUTOFF DATE (today): 2025-11-24
Regulator: SEBI (IN)
Matter: SEBI consultation: ease-of-doing-business modifications to master circular provisions on administration of stock exchanges
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2025-10-08 | official-forward (B) | consultation_paper | "Consultation Paper on Measures for ease of doing business on Administration of Exchanges" | www.sebi.gov.in
   Claims: First in a series of ease-of-doing-business consultation papers reviewing SEBI's exchange-related master circulars, implementing a FY2023-24 budget announcement on consultative compliance simplification. / Proposes modifications to Chapter 6 (Administration of Stock Exchanges) of the Master Circular for Stock Exchanges and Clearing Corporations, and related chapters of the Master Circular for Commodity Derivatives Segment. / Covers administration of stock exchanges including commodity derivatives exchanges.
   Excerpt: CONSULTATION PAPER ON ADMINISTRATION OF STOCK EXCHANGES- FOR PUBLIC COMMENTS. Measures for ease of doing business for MIIs- " Modifications to Master Circular for Stock Exchanges and Clearing Corporations, Master Circular for Commodity Derivatives Segment on Administration of Stock Exchanges (including Commodity Derivatives Exchanges)". The Hon'ble Finance Minister in the budget announcements for FY 2023-24, inter-alia, made an announcement to simplify, ease and reduce cost of compliance for participants in the financial sector through a consultative process.
---
## SNAPSHOT S66c419a55a
CUTOFF DATE (today): 2025-11-24
Regulator: SEBI (IN)
Matter: SEBI consultation: standardising the process for opening mutual fund folios and executing the first investment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sd1bd1b667d
CUTOFF DATE (today): 2022-11-26
Regulator: FDA (US)
Matter: FDA draft guidance: Adjusting for Covariates in Randomized Clinical Trials for Drugs and Biological Products
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S21790abc4e
CUTOFF DATE (today): 2026-08-25
Regulator: SEBI (IN)
Matter: SEBI consultation: investor consent and conflicted-transaction thresholds for Alternative Investment Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-06-30 | official-forward (B) | consultation_paper | "Consultation paper on rationalizing the requirement of obtaining investor consent and ambit of conflicted transactions requiring investor consent under SEBI (Alternative Investment Funds) Regulations, 2012" | www.sebi.gov.in
   Claims: Proposes to standardize the process and methodology by which AIFs obtain investor consent under AIF Regulations, including for conflicted transactions. / Proposes to bring consistency to the unitholder-approval threshold prescribed across different AIF Regulations provisions and circulars. / Proposes to rationalize the ambit/scope of 'conflicted transactions' that require investor consent, including revisiting the definition of 'associate'. / States that diverse market practice has emerged on solicitation, voting methodology and treatment of non-responses, creating interpretational uncertainty.
   Excerpt: With an approach to strike a balance between operational and investment flexibility for AIFs, while ensuring that investors are able to make informed decisions, this consultation paper seeks comments and views from the public and stakeholders on the following proposals - 1.1. To standardize the process of obtaining investor consent as per requirements mandated under AIF Regulations, including, for carrying out conflicted transactions; 1.2. To bringing consistency in threshold for unitholder approval prescribed under AIF Regulations and circulars issued thereunder; and, 1.3. To rationalize the ambit of conflicted transactions which would require investor consent, in a manner that aligns with the underlying regulatory intent.
---
## SNAPSHOT S2a97ab0880
CUTOFF DATE (today): 2022-06-22
Regulator: FDA (US)
Matter: FDA draft guidance: Select Updates for Unique Device Identification: Policy Regarding Global Unique Device Identification Database Requirements for Certain Devices
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S9c4517be40
CUTOFF DATE (today): 2024-09-17
Regulator: FDA (US)
Matter: FDA draft guidance: Review of Drug Master Files in Advance of Certain Abbreviated New Drug Application Submissions Under Generic Drug User Fee Amendments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT S52880e6b19
CUTOFF DATE (today): 2021-05-24
Regulator: FDA (US)
Matter: FDA draft guidance: Premenopausal Women With Breast Cancer: Developing Drugs for Treatment
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.
---
## SNAPSHOT Scd126be9be
CUTOFF DATE (today): 2026-07-13
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing use of historical price scenarios in stress testing for the Commodity Derivatives Segment
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence: none provided for this snapshot.
---
## SNAPSHOT Sb758e1ecef
CUTOFF DATE (today): 2025-06-18
Regulator: FDA (US)
Matter: FDA draft guidance: Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2021-06-28 | official-forward (B) | draft_guidance_availability_notice | "Sponsor Responsibilities-Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/Bioequivalence Studies; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies." The draft gu
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Sponsor Responsibilities--Safety Reporting Requirements and Safety Assessment for Investigational New Drug Application and Bioavailability/ Bioequivalence Studies." The draft guidance provides recommendations for sponsors and sponsor-investigators to comply with the requirements of investigational new drug application (IND) safety reporting and safety reporting for bioavailability (BA) and bioequivalence (BE) studies. In doing so, the guidance provides recommendations related to the two IND safety reporting provisions that require assessment of aggregate data to facilitate appropriate IND safety reporting practices. An earlier draft guidance for industry entitled "Safety Assessment for IND Safety Reporting" (December 2015) (the 2015 draft guidance) has been incorporated into this draft guidance. However, this content was revised to address feedback from stakeholders and comments received on the 2015 draft guidance. Concurrent with the publication of this draft guidance, we are withdrawing the 2015 draft guidance. Additionally, this draft guidance incorporates c
---
## SNAPSHOT Scd15bf98fd
CUTOFF DATE (today): 2022-07-07
Regulator: FDA (US)
Matter: FDA draft guidance: Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2019-07-01 | official-forward (B) | draft_guidance_availability_notice | "Instructions for Use-Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products-Content and Format; Draft Guidance for Industry; Availability" | www.federalregister.gov
   Claims: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Instructions for Use--Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products--Content and Format." This dr
   Excerpt: The Food and Drug Administration (FDA or Agency) is announcing the availability of a draft guidance for industry entitled "Instructions for Use--Patient Labeling for Human Prescription Drug and Biological Products and Drug-Device and Biologic-Device Combination Products--Content and Format." This draft guidance provides recommendations for developing the content and format of an Instructions for Use (IFU) document for human prescription drugs and biological products and drug-device or biologic-device combination products submitted under a new drug application (NDA) or a biologics license application (BLA). The IFU is developed by applicants for patients who use drug products that have complicated or detailed patient-use instructions. The recommendations in this draft guidance are intended to help develop consistent content and format across IFUs and to help ensure that patients receive clear, concise information that is easily understood for the safe and effective use of prescription drug products.
---
## SNAPSHOT S320ad215eb
CUTOFF DATE (today): 2026-06-08
Regulator: SEBI (IN)
Matter: SEBI consultation: reviewing base price and price band methodology for Exchange Traded Funds
Decisive action for this matter = the regulator's first official publication ADOPTING the proposal at least in substantial part (e.g., board decision press release, circular, or notified regulation).
Evidence available as of the cutoff (1 item(s), chronological):
[E1] 2026-02-13 | official-forward (B) | consultation_paper | "Consultation Paper on Review of provisions related to Base Price and Price Bands for Exchange Traded Funds (ETFs)" | www.sebi.gov.in
   Claims: Seeks public comments on proposals to revise the base price and price-band methodology specifically for Exchange Traded Funds (equity, debt and commodity ETFs including Gold/Silver ETFs). / Notes the current fixed price band of +/-20% (+/-5% for Overnight ETFs) is applied to a base price equal to the T-2 day NAV of the ETF, creating a one-trading-day lag. / Frames the issue as the fixed band and NAV lag not being commensurate with the price range of the ETF's underlying assets.
   Excerpt: The objective of this consultation paper is to seek public comments on the proposals on Base Price and Price Bands for Exchange Traded Funds (ETFs). ETF is a mutual fund scheme that invests in securities in the same proportion as an index of securities and the units of exchange traded fund are mandatorily listed and traded on exchange platform... Currently, there are individual scrip wise price bands of up to 20% either way, applicable for all scrips in the rolling settlement except for the scrips on which derivatives products are available.
---
## SNAPSHOT Scbc2ee2c7e
CUTOFF DATE (today): 2025-05-21
Regulator: FDA (US)
Matter: FDA draft guidance: Patient-Focused Drug Development: Selecting, Developing, or Modifying Fit-for-Purpose Clinical Outcome Assessments
Decisive action for this matter = the agency publishes the FINAL version of this guidance.
Evidence: none provided for this snapshot.